cyrilzakka/clinical-trials huggingface dataset:
A Clinical Trial to Study the Effect of Imagined Progressive Movements in Patients With Paralysis of One Side of the Body.

The aim of the Study to evaluate the effect of Graded motor imagery on upper limb motor functions and quality of life in patients with stroke that was conducted in two centers in india. The primary outcome measures were upper limb motor functions at 6 weeks and secondary outcome measure was quality of life at 6 weeks.

Research Hypothesis: There would be significant effect of GMI on Upper limb motor functions and quality of life in patients with stroke.

Graded Motor Imagery (GMI) is essentially a brain based treatment, targeting the activation of different brain regions in a graded manner. GMI is a three stage treatment programme comprising of Left Right discrimination training, Explicit Motor imagery and Mirror therapy.

In this Study, GMI approach is applied on the patients with Stroke to enhance their Upper limb motor functions and Quality of life.

Conventional treatment:

Patients of group A and group B had received conventional treatment for 6 weeks. Conventional treatment consists of Task oriented upper extremity functional exercises. Components of Task oriented training include weight bearing, supportive reactions, and reaching, grasping, holding and release activities. It was performed five days a week for six weeks of one hour duration.

Graded Motor Imagery:

Patients of group A had received GMI programme with conventional treatment for 6 weeks. It is a three stage process, was performed five days a week for six weeks of one hour duration. It comprises of:

* Left Right discrimination training (Implicit Motor Imagery) - 2 weeks
* Explicit Motor Imagery (Imagined movements) - 2 weeks
* Mirror Therapy - 2 weeks

Eligibility Criteria:
Inclusion Criteria:

* Age (between 45 to 65 years)
* Individuals who experienced one episode of stroke only.
* Both males and females were included in the study
* Both ischemic \& haemorrhagic stroke individuals were included in the study
* Duration of stroke between 1 to 6 months
* Mini mental status examination (MMSE) (score \> 23)
* Patients with Brunnstrom stage 1 \& 2

Exclusion Criteria:

* Individuals having any musculoskeletal disorders
* Individuals having any neurological disorder other than stroke
* Individuals with any visual impairment
* Individuals having any systemic disease
* Non cooperative patients
* Patients suffering from psychological problems
Receiving Genetic Information: A Quantitative Survey

This study will evaluate the public's response to receiving genetic information via an electronic platform. It will comprise of an internet run quantitative survey.

There is currently a high prevalence of obesity in the UK. Diets personalised to an individual's genetics could help to reduce the prevalence. However, how the public will respond to this information is unknown. The use of technology is very common and could provide an accessible platform to communicate genetic results to the public. Therefore, this study will evaluate the public's response to receiving genetic information via an electronic platform.

This study will comprise of an internet run quantitative survey. The survey will be circulated using relevant websites, internet forums, emails and social media. Participants will be required to complete the survey once which will take around 10 minutes. The participants will not be required to complete the survey in a controlled setting, it may be complete wherever the participant feels comfortable. Data analysis will take place at St Mary's University.

Eligibility Criteria:
Inclusion Criteria:

UK citizens between the ages of 18 and 65 years
A Comparative Analysis of Myopia Prevalence Among Madarsa Students vs. Non-Madarsa Students in Sukkur

Myopia (nearsightedness) has become a major global health concern, particularly among students, due to factors such as prolonged screen time, close-up work, and limited outdoor activities. In regions like Sukkur, Pakistan, the educational environments and lifestyles of students in Madarsas (religious schools) differ significantly from those in non-Madarsa (regular) schools, potentially influencing the prevalence of myopia. This comparative cross-sectional study aims to assess and compare the prevalence of myopia among Madarsa and non-Madarsa students in Sukkur.

The study will be conducted at Al Shifa Trust Eye Hospital over six months, involving students aged 5-20 years. Informed consent will be obtained from parents or guardians, and a structured questionnaire will collect data on lifestyle factors such as time spent on near work, outdoor activities, family history of refractive errors, and the use of corrective eyewear. Visual acuity and refractive errors will be assessed using standard eye charts, cycloplegic refraction, and measurements of keratometry, biometry, and axial length. The data will be analyzed using descriptive statistics, including frequencies, means, and standard deviations, with normality tests applied to continuous variables. Chi-square tests and Independent t-tests will be used for comparative analysis, while logistic regression will assess risk factors associated with myopia. The study will help determine the prevalence of myopia and its contributing factors in these student populations, informing potential interventions.

Eligibility Criteria:
Inclusion Criteria:

* Students aged 5-20 years.\[18\]
* Students of Sukkur enrolled in either Madarsa or schools.
* Parents or guardians who understand and sign the informed consent form.
* Students who are willing to undergo an eye examination and complete the research

Exclusion Criteria:

* Students with known systemic diseases or eye conditions (e.g., cataracts, retinal diseases) that could influence the assessment of myopia.
* Students who have had corrective eye surgery (e.g., LASIK) or those who have worn contact lenses or glasses for less than 3 months.
* Students unable to participate due to language barriers or other communincation difficulties
* Students with neurological conditions affecting vision
* Students unable to cooperate with visual acuity testing due to cognitive impairments"
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread

Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world


Eligibility Criteria:
Inclusion Criteria:

* Patients with unresectable or metastatic renal cell carcinoma who are initiating treatment for the first time with Yervoy and Opdivo in accordance with the Japanese package insert will be included in this PMS

Exclusion Criteria:

* Patients receiving combination therapy with Yervoy and Opdivo for non RCC indication will be excluded from this PMS

Other protocol defined inclusion/exclusion criteria could apply
CuidaTXT: a Text Message Dementia-caregiver Intervention for Latinos

Latino families with dementia experience substantial disparities in access to caregiver support compared to their non-Latino white peers, putting them at an increased risk for negative emotional, physical and financial outcomes. This R21 will address this research gap by 1) Developing a culturally and linguistically appropriate text message intervention for caregiver support among Latino family caregivers of individuals with dementia and 2) Testing the feasibility and acceptability of CuidaTXT, a multicomponent text message caregiver support intervention culturally and linguistically tailored for the Latino community.

Latino relatives of individuals with dementia are less likely than non-Latino whites to have access to caregiver support. Text messaging can dramatically enhance the reach of effective culturally and linguistically tailored caregiver support interventions. However, to our knowledge, no text message interventions exist to provide caregiver support among caregivers of individuals with dementia. Text message interventions can capitalize on the fact that Latinos own cellphones and use them to text at a higher rate than non-Latino whites. The overall aim of this proposal is to develop and test the first text message intervention for caregiver support of individuals with dementia among Latinos. This intervention, CuidaTXT \[Spanish for self-care and texting\], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources. This research corresponds with Stage 1 of the NIH Stage Model for Behavioral Intervention Development. In Aim 1, researchers will develop a culturally and linguistically appropriate text message intervention for caregiver support among Latino family caregivers of individuals with dementia using user-centered design methods. In Aim 2, researchers will test the feasibility and acceptability of CuidaTXT during six months.

Eligibility Criteria:
Inclusion Criteria:

* Spanish and English-speaking individuals
* Over the age of 18
* Identify as Latino
* Report providing hands-on care for a relative who has been given a clinical or research dementia diagnosis
* Care recipient has an AD-8 screening score greater than or equal to 2, indicating cognitive impairment
* Self-report being able to read and write
* Self-report owning a cell phone with a flat fee and use it at least weekly for texting

Exclusion Criteria:

-
Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280

The study is carried out in order to determine the relationship between the dose of AZD6280 and the blood concentration of AZD6280, and to investigate to which extent AZD6280 binds to GABAA receptors


Eligibility Criteria:
Inclusion Criteria:

* Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg
* Clinically normal physical findings, medical history and laboratory values.

Exclusion Criteria:

* Clinically significant illness or clinical relevant trauma within 2 weeks before the study start.
* History of clinically significant heart arrythmias or heart disease/problems.
* Previous participation in a PET study within the past 12 months. Suffer from claustrophobia and would be unable to undergo MRI (magnetic resonance imaging) or PET scanning.
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE

To determine whether 3 months' anticoagulation is as good as or better than 6 months' for the treatment of DVT/PE

Multi-centre trial involving 46 hospitals in the United Kingdom, with patients entered by 137 Consultant Physicians. Consenting patients were randomised in a central office to either 3 months' or 6 months' anticoagulation. Information on progress of the patients was requested by the co-ordinating office at 3 months, 6 months and 12 months. Outcomes were measured as death from DVT/PE, non-fatal extensions or recurrences of DVT/PE and major haemorrhages during and after anticoagulation.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years or more with suspected or proven DVT/PE whom the clinician intended to anticoagulate.

Exclusion Criteria:

* DVT/PE severe enough to require thrombolysis or pulmonary embolectomy.
* DVT/PE in the preceding 3 years.
* Neoplasia diagnosed/treated within previous 3 years.
* Pregnancy.
* Known major thrombophilias.
* Prolonged or continuous immobility or confinement to bed.
* Previous allergy to heparin or warfarin.
* Requirement for long-term anticoagulation.
* Inability to give informed consent.
Strength Training and Different Subtypes of Parkinson´s Disease

The aim of this randomized controlled trial was to assess the impact of progressive resistance exercise (PRE) in PD patients with akinesia and rigidity (AR-subtype). The investigators hypothesized the intervention would have a beneficial effect on the study outcomes.

Twenty-eight patients with PD AR-type of both sexes, were recruited for this trial. Each participant were assigned randomly to either intervention (N=13) or control (N=15) group.

The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one. The control group followed their usual weekly physical activity routine.

All patients underwent antrophometrical and neuromuscular function assessment (CoP measurements -primary outcomes- and the Ten-Meters Walk Test -TMWT- -secondary outcomes-). In addition, they were asked to provide ratings for the Spanish validated versions of the the Freezing of Gait Questionnaire (FOG-Q, 6-item version) -secondary outcomes-, the 39-item Parkinson ́s disease Questionnaire (PDQ39) -secondary outcomes- and the MDS-UPDRS -secondary outcomes-. Additionally, ratings of perceived exertion (RPE) (Borg \>6-20 scale) - secondary outcomes-, were recorded at the end of each PRE training session. Tests were carried out at three times: pre-test (before the training program), post-test (eight weeks after pre-tests, at the end of the training period), and four weeks after the post-test (re-test).

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with PD AR-type and Hoehn and Yahr Scale 1-2, (H\&Y)
* Do not express any type of dementia
* Able to stand for two min without assistance;
* Able to walk ten metres without assistance.

Exclusion criteria:

* To suffer a neurological disease other than PD.
* Do not meet some of the inclusion criteria.
Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors

The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Peginterferon alfa-2b is safe, effective in the treatment of patients with metastatic thymic epithelial tumors.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years;
2. Histologically proven Thymic epithelial tumors；
3. Stage IV according to UICC stage system(version 8,2017), at least with two evaluable abscopal lesions (≥1cm)（excluding intestinal metastasis）;
4. Evaluated as effective or stable disease after first-line chemotherapy or progressed after second-line chemotherapy (progression sites were no more than three sites);
5. ECOG performance status: 0-1;
6. Life expectancy ≥ 3 months.
7. Adequate baseline organ and marrow function: absolute neutrophil count greater than 1500 cells per μL, platelet concentration of greater than 50 000 per μL, total bilirubin less than 1•5 times the upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the ULN, and serum creatinine less than 1•5 times the ULN;
8. Female subjects have a negative urine or serum pregnancy test within 1 week prior to treatment if of childbearing potential;
9. Asymptomatic subjects with brain metastasis can be included, but the sites of brain cannot be considered as target sites;
10. Asymptomatic subjects with bone metastasis can be included, but the sites of bone cannot be considered as target sites.

Exclusion Criteria:

1. Having received immunotherapy within 4 weeks prior to inclusion;
2. Allergic to GM-CSF, INF-α2b or diagnosed with immune system disease, receiving immunosuppressant, such as prednisone, dexamethasone, methylprednisolone, methotrexate, hydroxychloroquine, cyclophosphamide, azathioprine and so one;
3. receiving treatment of other trials;
4. Any unstable systemic disease, including active infection, symptomatic congestive heart failure,myocardial infarction onset six months before included into the group, unstable angina, and severe arrhythmia, uncontrolled chronic lung disease;
5. unwilling to sign consent;
6. Women in pregnancy or lactation;
7. Other malignancy except for non-melanoma carcinoma of the skin or in situ carcinoma of the cervix.
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

The purpose of this study is to assess the effect of Diclofenac Sodium Topical Gel (DSTG) on injection site reaction following self-administer glatiramer acetate in people with Multiple Sclerosis.

A 4 week study with active or placebo medication at randomization and switch treatment at 2-week crossover visit (2 weeks on each arm). There will be a total of 3 visits to the clinic. Subjects will receive instruction on how to apply the DSTG/placebo at the injection site and keep a daily injection site reaction diary.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Multiple Sclerosis (MS) made at least 3 months prior based on McDonald or Poser criteria.
* Age 18 or more
* Ongoing treatment with glatiramer acetate (Copaxone) for three months or more.
* No MS exacerbation for 60 days prior to screening.
* Mean score of greater than or equal to 1.0 on screening Local Injection Site Reaction scale of last 3 days.
* Written informed consent.

Exclusion Criteria:

* Regular use of any non-steroidal anti-inflammatory drug (NDAID), except Asprin (\<325 mg daily), between screening and end of study.
* Any contraindication to Diclofenac Sodium Topical Gel (DSTG)

  * allergy to DSTG or any NSAID.
  * history of asthma, urticaria, or other allergic reaction after taking any NSAID.
* Females who are breast feeding, pregnant or have potential to become pregnant during the course of the study(fertile and unwilling/unable to use effective contraceptive measures).
* Cognitive deficits that would interfere with the subject's ability to give informed consent or preform study testing.
* Any other serious and/or unstable medical condition.
Airway Basal Stem Cell Therapy in Chronic Obstructive Pulmonary Disease (COPD)

This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous bronchial basal cell therapy, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic respiratory condition characterized by persistent airflow limitation and impaired lung function, leading to significant morbidity and mortality worldwide. Current treatments primarily focus on symptom management and have limited impact on disease progression or survival. This study proposes a novel approach using autologous bronchial basal cells, which have demonstrated the potential to repair damaged lung tissue and improve lung function in preclinical studies. The therapy involves the collection of bronchial basal cells via bronchial brushing, followed by their expansion and reintroduction into the patient's lungs via bronchoscopic infusion. The primary objective is to assess the improvement in lung diffusion capacity (DLCO), with secondary endpoints including changes in lung ventilation function (FEV1, FVC) and quality of life (CAT score). The study will also monitor safety, including the incidence of adverse events. Eligible participants are COPD patients aged 40-80 with moderate to severe disease. The trial includes a screening phase, cell collection, transplantation, and follow-up assessments at 4 and 24 weeks post-treatment. This study represents a promising advancement in regenerative medicine for COPD, offering a potential therapeutic option that addresses the underlying structural damage in the lungs.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD);
2. Post-bronchodilator FEV1/FVC \<70%;
3. DLCO ≥20% and \<80% of predicted value.

Exclusion Criteria:

1. Pregnant, breastfeeding, or planning to become pregnant within 1 year after treatment (or male participants planning for their spouse to become pregnant);
2. Positive for syphilis (TP-Ab), HIV, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies;
3. Current or past history of malignancy.
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors

The overall aim of the study is to develop and validate a Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) clinical prediction model (screening tool) based on risk factors to guide screening for ILD in patients with RA using High Resolution Computed Tomography (HRCT).


Eligibility Criteria:
Inclusion criteria:

1. Adult patients with RA according to 1987 American College of Rheumatology (ACR) or 2010 ACR / European League Against Rheumatism (EULAR) classification of RA, with any RA duration
2. Patient must have ≥ 2 of the following risk factors for ILD (i.e., any 2 or more):

   * Male
   * Current or previous smoker
   * Age of ≥ 60 years at RA diagnosis
   * Rheumatoid factor high-positive (titer \> 3x upper limit of normal) AND/OR anti-cyclic citrullinated peptide (anti-CCP) high-positive (titer \> 3x upper limit of normal) at RA diagnosis or any time after RA diagnosis
   * High/severe RA disease activity score at screening visit or within 12 months of screening visit, as defined with any of the following measures: Disease Activity Score-28 (DAS-28), Clinical Disease Activity Index (CDAI), Routine Assessment of Patient Index Data 3 (RAPID-3), Simple Disease Activity Index (SDAI), Patient Activity Scale (PAS), PAS-II
   * Presence or history of these extra-articular manifestations of RA: vasculitis, Felty's syndrome, secondary Sjogren's syndrome, cutaneous rheumatoid nodules, serositis and/or scleritis/uveitis

Exclusion criteria:

1. Patients previously diagnosed with any ILD or interstitial lung abnormality (ILA)
2. Patients who have had a chest computerized tomography (CT) in the past 2 years
3. Pregnancy at time of HRCT (to be checked in women of child-bearing potential before scan)
4. Unwilling or unable to obtain HRCT
5. Patients previously received drugs or treatments that are known to induce ILD (e.g., radiation therapy to chest region, bleomycin). Note: All disease-modifying antirheumatic drugs (DMARDs) including methotrexate and biologics are allowed.
6. Patients who have had a lung transplant
7. Patients suspected of having developed ILD due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection / coronavirus disease 19 (COVID-19) (based on Investigators' judgement)
8. Patients diagnosed with another autoimmune disorders overlapping with RA-associated with the development of ILD (systemic sclerosis, myositis, dermatomyositis, mixed connective tissue disease, systemic lupus erythematosus, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis or primary Sjogren's syndrome)
9. Patients currently enrolled in an investigational new drug trial